ColonAiQ

The ColonAiQ test is a highly sensitive and specific blood-based genetic screening tool designed to detect colorectal cancer at an early stage. By analyzing abnormal DNA methylation patterns from free circulating DNA in the bloodstream, the test can identify cancer-associated changes long before symptoms appear. ColonAiQ provides a convenient, minimally invasive alternative to colonoscopy for early detection, risk assessment, and post-treatment monitoring, helping patients take proactive steps to prevent advanced colorectal cancer.

Please Log In to access Additional Details and documents ..

• What colorectal cancer is: How benign polyps can develop into malignant tumors over 5–10 years, often without symptoms in the early stages.
  
  

• Predisposing factors and symptoms: Increased risk due to sedentary lifestyle, low-fiber diets, smoking, alcohol use, and genetic predisposition; typical symptoms include abdominal pain, bloating, blood in the stool, and anemia.
  
  

• Free circulating DNA in cancer screening: Explanation of cell-free DNA, how it enters the bloodstream, and how liquid biopsy technology can detect cancer-related genetic markers.
  
  

• Basics of the ColonAiQ genetic test: A multi-gene methylation test analyzing methylation patterns in specific genes and gene regions associated with colorectal cancer.
  
  

• Benefits of the ColonAiQ test: High specificity and sensitivity, early detection capability, usefulness for monitoring recurrence or metastasis, and superior performance compared to similar non-invasive tests.
  
  

• Why testing with ColonAiQ is recommended: Importance of early screening, especially for individuals over 50 or with risk factors; the test’s accuracy and the curability of cancer when detected early.
  
  

• Preparing for the test: A simple, quick procedure requiring only an 8 ml blood sample, with no special preparation needed.